AtheroNova Inc. to Address Significant Increase in Ischemic Stroke Occurrence in Americans Under 45

IRVINE, CA--(Marketwire - March 01, 2011) - AtheroNova Inc. (OTCBB: AHRO) (“AtheroNova”), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, addressed a study presented at the American Stroke Association (ASA) conference that found a dramatic statistically significant increase in ischemic stroke hospitalizations among males and females in all age groups from 5 to 44 years old.

“The research presented at the ASA conference demonstrates the drastic toll that atherosclerosis is taking among a significantly younger population group than was previously thought to be at such high risk from soft vulnerable plaque,” stated Thomas W. Gardner, CEO of AtheroNova. “With our second round pre-clinical studies evaluating the atherosclerotic plaque regression efficacy of our compounds now in progress at two major research centers, this study adds to the body of clinical evidence demonstrating that atherosclerotic plaque is a huge and growing problem that must be addressed from early childhood onwards.”

“The evidence indicating that atherosclerosis is a lifelong problem only emphasizes the pressing need for the development of safe and effective treatments that can go beyond slowing the buildup of dangerous plaque deposits to actually demonstrate regression. Following the completion of our second round pre-clinical program expected within the next six months, we look forward to the filing of an Investigative New Drug application for our plaque regression compounds and the commencement of Phase I human trials,” added Mr. Gardner.

About AtheroNova

AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the preclinical trials being conducted for the Company, the expected time to completion of the research and the ongoing development for AtheroNova’s plaque regression compounds. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova’s filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.